Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.32 |
---|---|
High | 5.41 |
Low | 5.07 |
Bid | 5.05 |
Offer | 5.39 |
Previous close | 5.22 |
Average volume | 412.41k |
---|---|
Shares outstanding | 22.17m |
Free float | 15.80m |
P/E (TTM) | -- |
Market cap | 115.74m USD |
EPS (TTM) | -2.06 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
Announcements
- INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
- INmune Bio Announces $13.0 Million Registered Direct Offering
- INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
- INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
- INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
- INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
- INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
- INmune Bio Inc. to Join Russell 3000® Index
- INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
- INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
More ▼